Cargando…
Palliative treatment with radiation-emitting metallic stents in unresectable Bismuth type III or IV hilar cholangiocarcinoma
BACKGROUND: The emerging data for stenting in combination with brachytherapy in unresectable hilar cholangiocarcinoma are encouraging. The aim of this study was to evaluate the efficacy and safety of radiation-emitting metallic stents (REMS) for unresectable Bismuth type III or IV hilar cholangiocar...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604711/ https://www.ncbi.nlm.nih.gov/pubmed/29018577 http://dx.doi.org/10.1136/esmoopen-2017-000242 |
_version_ | 1783264907254300672 |
---|---|
author | Lu, Jian Guo, Jin-He Zhu, Hai-Dong Zhu, Guang-Yu Wang, Yong Zhang, Qi Chen, Li Wang, Chao Pan, Tian-Fan Teng, Gao-Jun |
author_facet | Lu, Jian Guo, Jin-He Zhu, Hai-Dong Zhu, Guang-Yu Wang, Yong Zhang, Qi Chen, Li Wang, Chao Pan, Tian-Fan Teng, Gao-Jun |
author_sort | Lu, Jian |
collection | PubMed |
description | BACKGROUND: The emerging data for stenting in combination with brachytherapy in unresectable hilar cholangiocarcinoma are encouraging. The aim of this study was to evaluate the efficacy and safety of radiation-emitting metallic stents (REMS) for unresectable Bismuth type III or IV hilar cholangiocarcinoma. PATIENTS AND METHODS: Consecutive patients who underwent percutaneous placement with REMS or uncovered self-expandable metallic stent (SEMS) for unresectable Bismuth type III or IV hilar cholangiocarcinoma between September 2011 and April 2016 were identified into this retrospective study. Data on patient demographics and overall survival, functional success, stent patency and complications were collected at the authors’ hospital. RESULTS: A total of 59 patients were included: 33 (55.9%) in the REMS group and 26 (44.1%) in the SEMS group. The median overall survival was 338 days in the REMS group and 141 days in the SEMS group (p<0.001). The median stent patency time was 385 days for REMS and 142 days for SEMS (p<0.001). The functional success rate (87.9% vs 84.6%, p=0.722) and incidence of overall complications (27.3% vs 26.9%, p=0.999) did not differ in the two groups. CONCLUSIONS: Placement with REMS is safe and effective in palliation for unresectable Bismuth type III or IV hilar cholangiocarcinoma, and seems to prolong survival as well as patency of stent in these patients. |
format | Online Article Text |
id | pubmed-5604711 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-56047112017-10-10 Palliative treatment with radiation-emitting metallic stents in unresectable Bismuth type III or IV hilar cholangiocarcinoma Lu, Jian Guo, Jin-He Zhu, Hai-Dong Zhu, Guang-Yu Wang, Yong Zhang, Qi Chen, Li Wang, Chao Pan, Tian-Fan Teng, Gao-Jun ESMO Open Original Research BACKGROUND: The emerging data for stenting in combination with brachytherapy in unresectable hilar cholangiocarcinoma are encouraging. The aim of this study was to evaluate the efficacy and safety of radiation-emitting metallic stents (REMS) for unresectable Bismuth type III or IV hilar cholangiocarcinoma. PATIENTS AND METHODS: Consecutive patients who underwent percutaneous placement with REMS or uncovered self-expandable metallic stent (SEMS) for unresectable Bismuth type III or IV hilar cholangiocarcinoma between September 2011 and April 2016 were identified into this retrospective study. Data on patient demographics and overall survival, functional success, stent patency and complications were collected at the authors’ hospital. RESULTS: A total of 59 patients were included: 33 (55.9%) in the REMS group and 26 (44.1%) in the SEMS group. The median overall survival was 338 days in the REMS group and 141 days in the SEMS group (p<0.001). The median stent patency time was 385 days for REMS and 142 days for SEMS (p<0.001). The functional success rate (87.9% vs 84.6%, p=0.722) and incidence of overall complications (27.3% vs 26.9%, p=0.999) did not differ in the two groups. CONCLUSIONS: Placement with REMS is safe and effective in palliation for unresectable Bismuth type III or IV hilar cholangiocarcinoma, and seems to prolong survival as well as patency of stent in these patients. BMJ Publishing Group 2017-09-14 /pmc/articles/PMC5604711/ /pubmed/29018577 http://dx.doi.org/10.1136/esmoopen-2017-000242 Text en © European Society for Medical Oncology (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Original Research Lu, Jian Guo, Jin-He Zhu, Hai-Dong Zhu, Guang-Yu Wang, Yong Zhang, Qi Chen, Li Wang, Chao Pan, Tian-Fan Teng, Gao-Jun Palliative treatment with radiation-emitting metallic stents in unresectable Bismuth type III or IV hilar cholangiocarcinoma |
title | Palliative treatment with radiation-emitting metallic stents in unresectable Bismuth type III or IV hilar cholangiocarcinoma |
title_full | Palliative treatment with radiation-emitting metallic stents in unresectable Bismuth type III or IV hilar cholangiocarcinoma |
title_fullStr | Palliative treatment with radiation-emitting metallic stents in unresectable Bismuth type III or IV hilar cholangiocarcinoma |
title_full_unstemmed | Palliative treatment with radiation-emitting metallic stents in unresectable Bismuth type III or IV hilar cholangiocarcinoma |
title_short | Palliative treatment with radiation-emitting metallic stents in unresectable Bismuth type III or IV hilar cholangiocarcinoma |
title_sort | palliative treatment with radiation-emitting metallic stents in unresectable bismuth type iii or iv hilar cholangiocarcinoma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604711/ https://www.ncbi.nlm.nih.gov/pubmed/29018577 http://dx.doi.org/10.1136/esmoopen-2017-000242 |
work_keys_str_mv | AT lujian palliativetreatmentwithradiationemittingmetallicstentsinunresectablebismuthtypeiiiorivhilarcholangiocarcinoma AT guojinhe palliativetreatmentwithradiationemittingmetallicstentsinunresectablebismuthtypeiiiorivhilarcholangiocarcinoma AT zhuhaidong palliativetreatmentwithradiationemittingmetallicstentsinunresectablebismuthtypeiiiorivhilarcholangiocarcinoma AT zhuguangyu palliativetreatmentwithradiationemittingmetallicstentsinunresectablebismuthtypeiiiorivhilarcholangiocarcinoma AT wangyong palliativetreatmentwithradiationemittingmetallicstentsinunresectablebismuthtypeiiiorivhilarcholangiocarcinoma AT zhangqi palliativetreatmentwithradiationemittingmetallicstentsinunresectablebismuthtypeiiiorivhilarcholangiocarcinoma AT chenli palliativetreatmentwithradiationemittingmetallicstentsinunresectablebismuthtypeiiiorivhilarcholangiocarcinoma AT wangchao palliativetreatmentwithradiationemittingmetallicstentsinunresectablebismuthtypeiiiorivhilarcholangiocarcinoma AT pantianfan palliativetreatmentwithradiationemittingmetallicstentsinunresectablebismuthtypeiiiorivhilarcholangiocarcinoma AT tenggaojun palliativetreatmentwithradiationemittingmetallicstentsinunresectablebismuthtypeiiiorivhilarcholangiocarcinoma |